FDA Supplement Label Compliance for Gummy Manufacturers: A Complete Guide

Why Label Compliance Is Non-Negotiable for Gummy Supplement Brands

If you manufacture gummy dietary supplements and sell them in the United States, your product label is a legal document. The FDA regulates dietary supplement labeling under 21 CFR Part 101 and enforces good manufacturing practice requirements — including those tied to labeling accuracy — under 21 CFR Part 111. Failing to meet these standards doesn't just expose you to a warning letter. It can result in import alerts, mandatory recalls, and marketplace bans from major retailers including Amazon, which now requires supplement sellers to meet specific label compliance thresholds before listing products.

For gummy manufacturers specifically, labeling compliance carries unique complications. Unlike tablets or capsules, gummies are a food-adjacent dosage form that consumers — especially children — may not immediately recognize as a supplement. That perception gap creates both a marketing temptation and a regulatory risk. The FDA has made clear that gummy supplements are dietary supplements first, and any claim, serving size, or ingredient representation on the label must be defensible under current regulations.

This guide is written for facility owners, QA managers, and production supervisors who need to understand not just what the rules are, but how they apply specifically to gummy products — from gelatin-based formats to pectin-based vegan alternatives, coated deposited gummies, and everything in between.

Mandatory Label Elements Under 21 CFR Part 101

Every dietary supplement sold in the U.S. must include a defined set of label elements, and gummies are no exception. The FDA requires these elements to appear in specific locations and formats. Missing or misplaced elements are among the most common triggers for Form 483 observations and warning letters. Here is what must appear on every gummy supplement label:

• Statement of Identity: The product must be clearly identified as a "Dietary Supplement." This phrase must appear on the principal display panel (PDP). Many gummy brands bury this language or stylize it in a way that makes it hard to read — both are compliance risks.
• Net Quantity of Contents: Must appear on the PDP and express the amount in both metric and U.S. customary units where applicable. For gummies, this typically means total count (e.g., "60 Gummies") and total weight.
• Supplement Facts Panel: Required on all dietary supplements. The format, font size, hierarchy of nutrients, and serving size declaration must follow 21 CFR 101.36 precisely.
• Ingredient List: All ingredients not listed in the Supplement Facts panel must appear in a separate ingredient list in descending order of predominance by weight. For gummies, this includes gelatin or pectin, glucose syrup, citric acid, natural flavors, colors, and coatings such as carnauba wax.
• Name and Place of Business: The name and address of the manufacturer, packer, or distributor must be included.
• Directions for Use: Required when the supplement is not ready to use or when the method of preparation affects use. For gummies sold to adults and children in the same product line, clear directions are critical.
• Warnings and Cautions: Including the required "Keep out of reach of children" statement and any allergen disclosures required under FALCPA.

One area where gummy manufacturers frequently run into trouble is the serving size declaration. Because gummies are unit-dose forms, serving size must reflect the number of gummies per serving — and that number must be consistent with what is actually delivered in terms of active ingredient potency. If your cooking and depositing process introduces variability in gummy weight or active concentration, your declared serving size may not accurately represent the dose a consumer receives. This is both a labeling issue and a 21 CFR Part 111 quality control issue.

Supplement Facts Panel Requirements Specific to Gummy Products

The Supplement Facts panel is the most scrutinized element of any dietary supplement label, and gummies present some format-specific challenges that tablets and capsules do not. The first issue is caloric content. Because gummies contain sugars — whether from glucose syrup, sucrose, or fruit-based sweeteners — they have caloric value that must be declared if it exceeds certain thresholds. The FDA requires calories, total carbohydrates, and total sugars to be listed in the Supplement Facts panel when they are present in nutritionally significant amounts.

This is a sharp contrast to a capsule or tablet, where caloric content is negligible. Gummy manufacturers who omit calorie and sugar declarations are routinely flagged during FDA inspections and by third-party retailers conducting label audits. If your gummy formula uses pectin with a high-sugar syrup base, you almost certainly need to declare calories and sugars — and your Supplement Facts panel layout must accommodate those rows properly.

Additional Supplement Facts considerations for gummy manufacturers include:

• Percent Daily Value (%DV): Must be listed for all nutrients with established DVs. If your gummy contains vitamin D, vitamin C, zinc, or other nutrients with established reference amounts, the %DV column must be populated correctly based on the actual quantified content per serving — not the theoretical added amount before cooking losses.
• Moisture and Bloom Loss During Processing: Active ingredient concentration in gummies can change during the cooking, depositing, and drying stages. High-temperature cooking can degrade heat-sensitive vitamins. Water activity management during drying can affect final gummy weight and therefore per-unit potency. Your label claims must reflect finished product testing, not pre-process formulation targets.
• Dual-Column Labeling: If your gummy is marketed to both children and adults (common in family supplement lines), you may need a dual-column Supplement Facts panel that lists values per serving for each population group.
• "Other Ingredients" Placement: Gummy-specific ingredients like carnauba wax coating, mogul starch residue, and gelatin source (porcine vs. bovine) must be accurately disclosed and are often missed or mischaracterized.

From a GMP standpoint under 21 CFR Part 111, your label claims are only as defensible as your in-process and finished product testing program. If you cannot demonstrate through batch records, COAs, and stability data that your finished gummies consistently contain what the label says, you have both a labeling violation and a manufacturing compliance gap.

Structure/Function Claims and Prohibited Claims on Gummy Labels

The marketing appeal of gummy supplements is undeniable — they are approachable, flavorful, and easy to take. That appeal drives brands to push claim language aggressively, and it is one of the primary reasons gummy supplement companies attract FDA scrutiny. Understanding the line between a permissible structure/function claim and an illegal drug claim is essential for anyone involved in label copy approval.

Structure/function claims describe the role of a nutrient or dietary ingredient in maintaining normal structure or function in the body. For example: "Vitamin C supports immune function" or "Magnesium supports normal muscle function." These are permissible provided you have substantiation for the claim, you notify the FDA within 30 days of first marketing, and you include the required disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

Where gummy brands consistently cross the line is with disease claims — either explicitly or implicitly. Phrases like "clinically proven," "reduces inflammation," "lowers blood sugar," or "prevents bone loss" move a product into drug territory. The FDA has issued multiple warning letters to gummy supplement companies for exactly this type of language. Social media content, website copy, and Amazon listing descriptions that make disease claims can also be considered labeling under FDA's broad definition of "labeling," which includes written material that accompanies or is associated with a product.

For gummies marketed to children, the scrutiny is even higher. Pediatric health claims require careful review, and any suggestion that a product treats ADHD, developmental delays, or childhood illness will trigger enforcement action. QA managers and brand teams should establish a formal claims review process — ideally with regulatory counsel — before any new gummy SKU goes to print or goes live on a marketplace.

Common Label Compliance Failures in Gummy Manufacturing Facilities

After conducting GMP audits and label reviews across dozens of gummy supplement facilities, the team at GummyGMP LLC has identified a consistent set of recurring compliance failures. These are the issues most likely to show up on an FDA Form 483 or result in a retailer compliance rejection:

1. Inaccurate Potency Claims Due to Process Variability: Gummy manufacturing involves high-temperature cooking that can degrade thermolabile ingredients like vitamins B1, B9, and C. If your Supplement Facts panel is based on the formulation input rather than finished product analytical testing, your label is almost certainly inaccurate. NSF GMP certification programs specifically evaluate whether label claims are verified by finished product testing.
2. Missing or Incorrect Allergen Declarations: Gelatin is derived from animal collagen — typically porcine or bovine — and while it is not a major allergen under FALCPA, some consumers have religious or dietary restrictions. More importantly, if your facility processes tree nuts, wheat, soy, or dairy in adjacent production runs, cross-contact allergen risks must be evaluated and disclosed appropriately. Mogul systems and shared depositing lines are common cross-contact vectors.
3. Non-Compliant Font Size and Panel Format: The FDA specifies minimum type sizes for label elements. Small gummy packaging — especially single-serve pouches or trial-size bottles — frequently fails to meet minimum font size requirements or compress the Supplement Facts panel in ways that violate format regulations.
4. Serving Size Inconsistency with Dosage Form: Stating "2 gummies" as a serving when your bottle contains an odd number of gummies (e.g., 45 gummies) creates a labeling discrepancy. Every gummy count, serving size, and servings-per-container value must be mathematically consistent and operationally achievable given your fill weight tolerances.
5. Outdated Label Versions in Production: Under 21 CFR Part 111, you are required to have label reconciliation procedures in place. Printing errors, version control failures, and use of obsolete artwork are among the most common 483 observations. Your document control system must ensure that only current, approved label artwork reaches the production floor.
6. Amazon-Specific Compliance Gaps: Amazon's supplement compliance program requires product images that clearly show a compliant Supplement Facts panel, ingredient list, and allergen information. Many gummy brands fail Amazon's automated compliance checks because their label photography is blurry, cropped incorrectly, or missing required panels entirely.

Correcting these failures is not just about regulatory risk mitigation — it is about brand credibility and consumer trust. A gummy supplement that is accurately labeled, honestly claimed, and consistently manufactured is a product that can scale. One that cuts corners on labeling is a liability waiting to surface.

Building a Label Compliance Program for Your Gummy Facility

Reactive label compliance — fixing problems after an FDA inspection or retailer rejection — is expensive and disruptive. A proactive, systematic label compliance program built into your quality management system is the only sustainable approach. Here is how to structure one for a gummy supplement manufacturing operation:

Start with a label review SOP that defines who reviews new and revised labels, what checklists are used, and what sign-offs are required before artwork is approved. This SOP should reference 21 CFR Part 101 and 21 CFR Part 111, and it should assign responsibility to a qualified individual — typically your QA manager or a designated regulatory affairs lead. Label review checklists should cover every required element, claim language, allergen disclosure, and panel format requirement.

Next, establish a finished product testing protocol that validates your label claims. For gummies, this means sending finished gummy samples — not bulk mix, not pre-deposited slurry — to an accredited third-party laboratory for potency testing. Results should be compared against label claims, and out-of-specification results should trigger a formal investigation before product is released. Stability testing under appropriate temperature and humidity conditions is also required to support shelf-life dating and to confirm that potency claims remain accurate throughout the labeled use-by period.

Finally, implement a label version control system within your document management infrastructure. Every approved label should have a version number, an approval date, and a list of associated batch numbers or production runs. Superseded labels must be removed from production areas and archived. This sounds basic, but version control failures are among the most frequently cited GMP deficiencies in gummy supplement facilities — and they are entirely preventable with the right systems in place.

At GummyGMP LLC, we work exclusively with gummy supplement manufacturers to build these systems from the ground up or strengthen existing programs before FDA inspections, NSF audits, or major retailer onboarding. If your label compliance program has gaps — or if you are preparing a new gummy product for launch — now is the time to get it right.